Inrebic
What Inrebic is used for
Inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Inrebic
- Active substance
- fedratinib
- Disease area
- Myeloproliferative Disorders; Primary Myelofibrosis
- Medicine group
- Antineoplastic agents
- ATC code
- L01EJ02
- Marketing authorisation holder
- Bristol Myers Squibb Pharma EEIG
- Authorised in the EU since
- 2021
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Inrebic used for?
Inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
What is the active substance in Inrebic?
Inrebic contains fedratinib.
Who makes Inrebic?
The EU marketing authorisation holder is Bristol Myers Squibb Pharma EEIG.
Is Inrebic an orphan medicine?
Yes. Inrebic is designated an orphan medicine in the EU, for a rare disease (Myeloproliferative Disorders; Primary Myelofibrosis).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU